2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-124015
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one 177987-23-4 98%
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one (Compound 1) is an inhibitor of oleamide hydrolase.
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one
  • HY-124019
    4,5-DiHDPA lactone 845673-68-9 98%
    4,5-DiHDPA lactone (5), a derivative of docosahexaenoic acid (DHA), is a PPARγ activator.
    4,5-DiHDPA lactone
  • HY-124038
    RX-055 2108098-33-3 98%
    RX-055 is a diazirine-containing photoaffinity probe. RX-055 can be derived from WOBE437. RX-055 can irreversibly block membrane transport of endocannabinoids. RX-055 exerts site-specific anxiolytic effects in brain.
    RX-055
  • HY-124047
    RX 67668 40709-76-0 98%
    RX 67668 is a potent cholinesterase inhibitor with an IC50 of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. RX 67668 can reverse the neuromuscular blockade induced by D-tubocurarine. RX 67668 is a muscle relaxant used to relieve skeletal muscle fatigue.
    RX 67668
  • HY-124057
    RO5126946 1137233-79-4 98%
    RO5126946 is a selective, orally active α7 nAChR allosteric potentiator with EC50 values of 0.06 μM (hα7 nAChR) and 770 nM (α7 nAChR), and it crosses the blood-brain barrier. RO5126946 enhances synaptic transmission and positively modulates GABA-ergic responses by increasing peak current, slowing current decay, and elevating the frequency of spontaneous inhibitory postsynaptic currents, without affecting the recovery of receptors from the desensitized state. RO5126946 not only enhances subthreshold nicotine effects and improves associative learning, but also does not interfere with the original pro-cognitive effects of nicotine. RO5126946 can be used to study cognitive impairments associated with diseases such as Alzheimer's disease and schizophrenia.
    RO5126946
  • HY-124086
    BHQ-O-5HT 1417436-52-2 98%
    BHQ-O-5HT is a light-activated caged 5-HT protected by a BHQ group. When exposed to light at 365 or 740 nm, BHQ-O-5HT releases 5-HT through 1 or 2 photon excitation, respectively. BHQ-O-5HT can be manipulated in space and time to explore the role of 5-HT in regulating mood, appetite, memory, learning, and other cognitive functions.
    BHQ-O-5HT
  • HY-124109
    TRC051384 hydrochloride 1333327-56-2 98%
    TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke.
    TRC051384 hydrochloride
  • HY-124110
    TC299423 1975146-56-5 98%
    TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2? and α4β2? nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2? nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2? nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease.
    TC299423
  • HY-124117
    LY 278584 119193-37-2
    LY 278584 is a potent, highly selective 5-HT3 receptor antagonist with a Ki of 1.62 nM. LY 278584 has no activity on 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, or 5-HT2 receptors.
    LY 278584
  • HY-124135
    SB-656104 446020-51-5 98%
    SB-656104 is a potent antagonist of 5-HT7 receptor, with the pKi of 8.70, blocking 5-carboxamidotryptamine (5-CT) stimulated adenylyl cyclase activity.
    SB-656104
  • HY-124147
    FUB 465 184028-93-1 98%
    FUB 465 is an orally active inverse agonist at the constitutively active histamine H3 receptor with a pKi of 6.2 for H3 receptor. FUB 465 can be used in the research of central nervous system diseases.
    FUB 465
  • HY-124148
    Fenimide 60-45-7 98%
    Fenimide is an antipsychotic agent. Fenimide shows sedative, anticonvulsant and anesthetic activity. Fenimide has also prevented formation of stress-induced gastric lesions in the rat.
    Fenimide
  • HY-124152
    3,4-Dephostatin 173043-84-0 98%
    3,4-Dephostatin (Methyl-3,4-dephostatin) is an inhibitor of protein-tyrosine phosphatase (PTPase). 3,4-Dephostatin accelerates nerve growth factor (NGF)-induced neurite formation in PC12h cells. 3,4-Dephostatin sustains the NGF-induced tyrosine phosphorylation of proteins, most prominently that of mitogen-activated protein (MAP) kinase. 3,4-Dephostatin also prolongs epidermal growth factor (EGF)-induced tyrosine phosphorylation and activation of MAP kinase.
    3,4-Dephostatin
  • HY-124160
    JNJ-56022486 2036082-79-6 98%
    JNJ-56022486 is an orally active and potent negative AMPA receptor modulator (Ki=19 nM) selective for?TARP-γ8. JNJ-56022486 is also a TARP-γ8 receptor antagonist, with blood?brain?barrier (BBB) permeability. JNJ-56022486 can be used for research of Epilepsy.
    JNJ-56022486
  • HY-124186
    LR1143 150151-15-8 98%
    LR1143 is a dopamine transporter (DAT) and 5-HT uptake inhibitor, with IC50 values of 3.4 nM and 112 nM in rats, respectively. LR1143 binds to DAT labeled with the dopamine reuptake inhibitor GBR 12935 (HY-12242A), with an IC50 of 4.4 nM. LR1143 shows lower selectivity for DAT than for serotonin reuptake sites. LR1143 can be used in studies related to cocaine abuse.
    LR1143
  • HY-124204
    LY 274614 136109-04-1 98%
    LY 274614 is an orally active, competitive NMDA receptor antagonist. LY 274614 can be used for Neurological Disease study.
    LY 274614
  • HY-124223
    AF-DX 384 methanesulfonate 118290-27-0 98%
    AF-DX 384 (methanesulfonate) is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively). AF-DX 384 (methanesulfonate) reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine.
    AF-DX 384 methanesulfonate
  • HY-124264
    UBP710 1333111-40-2 98%
    UBP710 is a selective NMDA receptor modulator. UBP710 displays greater activity in potentiating GluN2B-containing receptors than those containing GluN2A.
    UBP710
  • HY-124266
    ML104 1314124-95-2 98%
    ML104 is a SMN1 gene modulator. ML104 is promising for research of neurological diseases.
    ML104
  • HY-124275
    ML389 1622294-25-0 98%
    ML389 is a highly selective vasopressin 1a (V1a) receptor antagonist (IC50=40 nM). ML389 is promising for research of central nervous system disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD).
    ML389
Cat. No. Product Name / Synonyms Application Reactivity